Chronic Diarrhea As An Early Gastrointestinal Symptom Of Cerebrotendinous Xanthomatosis
Published on: August 18, 2025
Chronic Diarrhea as an Early Gastrointestinal Symptom of Cerebrotendinous Xanthomatosis featured ima
Article author photo

Doua Ilyas

MPhil Pharmacy, Quaid-i-Azam University, Islamabad

Article reviewer photo

Naira Djuniardi

MPharm Pharmacy, King’s College London

Introduction

What if one week a child was having loose stools and growing weaker by the hour, and doctors were going back and forth among diagnoses, such as food allergies, infections, and irritable bowel syndromes? The baby fails to thrive, the loose stools persist and no one suspects that the genes, not the stomach, are at fault. Chronic diarrhoea might seem like an ordinary digestive problem, but it can in reality be an early indicator of cerebrotendinous xanthomatosis (CTX), an uncommon metabolic disorder that causes severe damage to the brain. The key to early detection and prevention of permanent damage could be found in this frequently ignored symptom. This article focuses on the significance of chronic diarrhoea as an early clinical sign that leads to the right diagnosis in an unusual but treatable disease, CTX, and explains how early diagnosis could impact a patient’s life.

Understanding Cerebrotendinous Xanthomatosis 

Cerebrotendinous xanthomatosis (CTX) is an uncommon disorder handed down in an autosomal recessive pattern. It arises from mutations in the CYP27A1 gene, which encodes sterol 27-hydroxylase, an enzyme vital for bile-acid synthesis. When the enzyme is deficient, the liver’s ability to convert cholesterol into bile acids falters, leading to the accumulation of cholestanol and bile alcohols in various tissues, including the gut, tendons, the central nervous system, and the lenses of the eyes.1 Although CTX affects only about 3 to 5 people in every 100,000, it is significantly underrecognised. Symptoms often begin in infancy or early childhood, presenting subtly and then spreading through multiple organ systems. Without prompt treatment, the disorder typically evolves into severe neurological and systemic complications by adulthood.2

Chronic Diarrhoea as an early sign

Chronic diarrhoea is defined as loose or watery stools persisting for four weeks or more. In cholesteryl ester transfer protein deficiency, the diarrhoea is usually prolonged, non-bloody, and does not improve with typical treatments. It often appears in early childhood, well ahead of the clearer signs of the condition, such as neurological problems or tendon xanthomas (cholesterol buildup on the tendons).3

Why diarrhoea happens

In CTX, diarrhoea stems from an underlying disturbance in metabolism. A net decrease in bile acid synthesis decreases the bile acid pool, impairing the emulsification and intestinal uptake of fats. Concurrently, bile alcohols, accumulating from disrupted metabolism, exert a toxic effect on the intestinal mucosa.4 The interplay of inadequate nutrient absorption, persistent diarrhoea, and steatorrhoea (high levels of fats in the stool) follows as a predictable consequence.

Chronic Diarrhoea: More than loose tools

Chronic diarrhoea often emerges as the first warning sign in children with CTX. Caregivers commonly report that the loose stools have been present since birth, or that fatty foods seem to make the situation worse. Over the months, the child presents with malnutrition, stagnant weight, and the gradual realisation that growth is delayed. What is striking is that, despite exhaustive laboratory and imaging work, the stools yield no hint of viral agents and nutritional screens are unrevealing.5 This symptom comes before the more serious manifestations such as:

  • Delayed milestones
  • Subtle cognitive declines 
  • Cataracts that appear in childhood
  • Tendon xanthomas, or ataxia combined with spasticity 

Therefore, in the face of unrelenting diarrhoea that defies explanation and is paired with growth failure or other discrete, systemic clues, CTX should remain in the differential, even early in the course of the illness.6

From Sign to Confirmation: When to Consider CTX

Learning that you have CTX can be a life-altering moment, though the diagnosis often arrives cloaked in confusion because the condition is so rare and the early signs can be very subtle. When chronic diarrhoea is among the symptoms, though, certain red flags should steer clinicians toward a deeper investigation: 

  • Early presentation of diarrhoea: starts during infancy or in the preschool years
  • Delayed or absent growth: the child fails to gain weight or height despite adequate feeding
  • Standard dietary adjustments and medications have no effect
  • Family history: other close relatives show the same symptom pattern, or the family has a known history of consanguineous marriage7 

Neurological symptoms may be mild or absent, yet subtle developmental delays or the first hint of early cataracts can still appear. When these features coincide, the healthcare team should keep CTX in mind and continue with targeted testing, guided by a strong, vigilant suspicion.

Diagnosis of CTX

Biochemical analysis levels of serum cholestanol

Elevated plasma cholestanol, frequently many times above the normal range, is the hallmark of CTX.

Specialised mass spectrometry techniques 

Specialised mass spectrometry techniques can be used to detect high levels of urine and plasma bile alcohols, which are caused by an impaired metabolism.

Genetic testing

By using genetic sequencing to find biallelic mutations in the CYP27A1 gene, a definitive diagnosis is made.

Imaging and systemic assessment

  • White matter alterations or cerebellar atrophy may be seen on a brain MRI, but these symptoms usually manifest later
  • Although very suggestive, tendon xanthomas (usually in the elbows or Achilles) don't show up until years after the disease has progressed
  • Early detection of juvenile cataracts may be possible with slit-lamp testing

Differential diagnoses

Children's chronic diarrhoea can have a number of causes, thus CTX should be distinguished from:

  • Coeliac illness
  • Fibrosis in cysts
  • Bowel inflammation
  • Insufficient pancreatic function
  • Inborn metabolic errors

The gradual multisystem involvement is what distinguishes CTX, particularly when diarrhoea is accompanied by neurological or developmental symptoms.8

The Significance of Early Recognition

Early recognition of CTX carries profound medical significance. Treatment is effective and recovery is far stronger when begun universally without delay. Consequently, patients who remain unrecognised endure progressive and often irreversible neurological deterioration, manifesting as ataxia, features indistinguishable from Alzheimer’s disease, pyramidal symptoms, and peripheral neuropathy. However, proactive surveillance of initial, subtle clues—most notably chronic diarrhoea—permits timely diagnosis and intervention, thereby circumventing the tragic sequelae that otherwise follow.9

Management and therapy

Chenodeoxycholic Acid (CDCA) Therapy

CDCA is the primary treatment for CTX. It suppresses bile acid synthesis in a feedback manner, which leads to:  

  • Inhibition of the formation of cholestanol  
  • Normal bile acid levels being achieved  
  • Enhanced absorption of fats  
  • Stopping and even reversing neurological function decline  

CDCA therapy can significantly reduce diarrhea within weeks of starting treatment.10  

Supportive Treatments  

  • Nutritional therapy for treating deficiencies, caused by malabsorption
  • Occupational and physical therapy for long-standing developmental delays  
  • Regular orthopaedic, neurological, and ophthalmological assessments  
  • Long-term follow-up with regular assessment of clinical status and cholestanol levels

Prognosis and Long-Term Outcomes

The expected outcomes in CTX depend on the timing of diagnosis. When diagnosed and treated in childhood during the pre-neurological stages, such as during episodes of diarrhea, patients have the potential to attain near-normal functionality. Chronic diarrhea responds to treatment with CDCA, and cataracts can be treated surgically. Postponing diagnosis to the second or third decade of life, on the other hand, greatly diminishes the prognosis due to irreversible damage to the central nervous system.8 This highlights the importance of timely intervention with early gastrointestinal signs, such as chronic diarrhea.

Summary

Chronic diarrhea is generally ignored as a normal pediatric ailment – a temporary condition connected to diet or mild infection. But in the context of Cerebrotendinous Xanthomatosis, this symptom is significantly more than a nuisance. It is a red flag, a window of opportunity, and quite perhaps the sole early warning before long-term damage sets in.

By diagnosing chronic diarrhea as a probable forerunner of CTX, doctors can treat before the condition leaves lasting brain damage. In a disease where time is brain, and every year without treatment brings irreversible injury, early suspicion can be the difference between lifelong handicap and a healthy future.

Let’s not overlook the message the gut is attempting to send you.

References

  1. Brass EP, Stelten BML, Verrips A. Cerebrotendinous xanthomatosis‐associated diarrhea and response to chenodeoxycholic acid treatment. JIMD Reports [Internet]. 2020 [cited 2025 Jul 21]; 56(1):105–11. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jmd2.12163.
  2. Nóbrega PR, Bernardes AM, Ribeiro RM, Vasconcelos SC, Araújo DABS, Gama VCDV, et al. Cerebrotendinous Xanthomatosis: A practice review of pathophysiology, diagnosis, and treatment. Front Neurol [Internet]. 2022 [cited 2025 Jul 21]; 13:1049850. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2022.1049850/full.
  3. Koyama S, Sekijima Y, Ogura M, Hori M, Matsuki K, Miida T, et al. Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments. JAT [Internet]. 2021 [cited 2025 Jul 21]; 28(9):905–25. Available from: https://www.jstage.jst.go.jp/article/jat/28/9/28_RV17055/_article
  4. .Yunisova G, Tufekcioglu Z, Dogu O, Bilgic B, Kaleagasi H, Akca Kalem S, et al. Patients with Lately Diagnosed Cerebrotendinous Xanthomatosis. Neurodegener Dis [Internet]. 2019 [cited 2025 Jul 21]; 19(5–6):218–24. Available from: https://karger.com/article/doi/10.1159/000506770.
  5. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds - ProQuest [Internet]. [cited 2025 Jul 21]. Available from: https://www.proquest.com/openview/0569691b45e96a2c36b795741fd68232/1?cbl=36214&pq-origsite=gscholar.
  6. Verrips A, Van Engelen BGM, Wevers RA, Van Geel BM, Cruysberg JRM, Van Den Heuvel LPWJ, et al. Presence of Diarrhea and Absence of Tendon Xanthomas in Patients With Cerebrotendinous Xanthomatosis. Arch Neurol [Internet]. 2000 [cited 2025 Jul 21]; 57(4):520. Available from: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneur.57.4.520.
  7. Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis [Internet]. 2014 [cited 2025 Jul 21]; 9(1):179. Available from: https://doi.org/10.1186/s13023-014-0179-4.
  8. Brass EP, Stelten BML, Verrips A. Cerebrotendinous xanthomatosis‐associated diarrhea and response to chenodeoxycholic acid treatment. JIMD Reports [Internet]. 2020 [cited 2025 Jul 21]; 56(1):105–11. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jmd2.12163.
  9. Kısa PT, Yildirim GK, Hismi BO, Dorum S, Kusbeci OY, Topak A, et al. Patients with cerebrotendinous xanthomatosis diagnosed with diverse multisystem involvement. Metab Brain Dis [Internet]. 2021 [cited 2025 Jul 21]; 36(6):1201–11. Available from: https://doi.org/10.1007/s11011-021-00714-7.
  10. Mignarri A, Gallus GN, Dotti MT, Federico A. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis [Internet]. 2014 [cited 2025 Jul 21]; 37(3):421–9. Available from: https://doi.org/10.1007/s10545-013-9674-3.
Share

Doua Ilyas

MPhil Pharmacy, Quaid-i-Azam University, Islamabad

I am a Registered Pharmacist graduated from Quaid-I-Azam University, Islamabad. I hold MPhil degree in Pharmaceutics from QAU Islamabad. I am currently working as Junior Lecturer at Ripah International University, Islamabad. I am interested in research work and academia. I am also working as a Medical Writer at klarity.health. I am a hardworking person and hold excellent academic record. I want to avail any opportunity that can help me learn more about my field and excel in it.

arrow-right